Tarsus Pharmaceuticals Stock Performance
| TARS Stock | USD 66.71 2.17 3.36% |
The entity has a beta of 0.48, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tarsus Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tarsus Pharmaceuticals is expected to be smaller as well. At this point, Tarsus Pharmaceuticals has a negative expected return of -0.0866%. Please make sure to validate Tarsus Pharmaceuticals' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Tarsus Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Tarsus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Tarsus Pharmaceuticals is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return (1.78) | Five Day Return (5.09) | Year To Date Return (20.09) | Ten Year Return 213.61 | All Time Return 213.61 |
1 | Tarsus Pharmaceuticals Is Up 6.1 percent After Analyst Upgrades Highlight XDEMVY Sales Momentum | 11/21/2025 |
2 | Disposition of 51885 shares by Azamian Bobak R. of Tarsus Pharmaceuticals subject to Rule 16b-3 | 12/04/2025 |
3 | Tarsus Pharmaceuticals stock hits all-time high at 83.67 USD - Investing.com | 12/08/2025 |
4 | Disposition of 6819 shares by Lin Elizabeth Yeu of Tarsus Pharmaceuticals subject to Rule 16b-3 | 12/15/2025 |
5 | Disposition of 2078 shares by Lin Elizabeth Yeu of Tarsus Pharmaceuticals at 79.5 subject to Rule 16b-3 | 12/16/2025 |
6 | Tarsus Pharmaceuticals Insider Sold Shares Worth 592,500, According to a Recent SEC Filing - marketscreener.com | 12/18/2025 |
7 | Will Tarsus Pharmaceuticals Inc. stock see PE expansion - Stock Correlation Metrics Learn to Trade Without Fear of Loss - Bollywood Helpline | 12/23/2025 |
8 | Disposition of 557 shares by Azamian Bobak R. of Tarsus Pharmaceuticals at 83.54 subject to Rule 16b-3 | 12/24/2025 |
9 | Disposition of 893 shares by Whitfield Dianne C. of Tarsus Pharmaceuticals at 82.93 subject to Rule 16b-3 | 01/02/2026 |
10 | BMRN or TARS Which Is the Better Value Stock Right Now | 01/13/2026 |
11 | Portfolio Update Does Tarsus Pharmaceuticals Inc have declining or rising EPS - Quarterly Earnings Report Long-Term Growth Plans - baoquankhu1.vn | 01/20/2026 |
12 | Universal Beteiligungs und Servicegesellschaft mbH Has 5.44 Million Stake in Tarsus Pharmaceuticals, Inc. TARS - MarketBeat | 01/27/2026 |
13 | Strs Ohio Has 624,000 Stake in Tarsus Pharmaceuticals, Inc. TARS | 01/30/2026 |
| Begin Period Cash Flow | 224.9 M | |
| Total Cashflows From Investing Activities | -199.2 M |
Tarsus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 7,150 in Tarsus Pharmaceuticals on November 4, 2025 and sell it today you would lose (479.00) from holding Tarsus Pharmaceuticals or give up 6.7% of portfolio value over 90 days. Tarsus Pharmaceuticals is currently does not generate positive expected returns and assumes 2.2663% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Tarsus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tarsus Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Tarsus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 66.71 | 90 days | 66.71 | under 95 |
Based on a normal probability distribution, the odds of Tarsus Pharmaceuticals to move above the current price in 90 days from now is under 95 (This Tarsus Pharmaceuticals probability density function shows the probability of Tarsus Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Tarsus Pharmaceuticals has a beta of 0.48. This usually implies as returns on the market go up, Tarsus Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Tarsus Pharmaceuticals will be expected to be much smaller as well. Additionally Tarsus Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Tarsus Pharmaceuticals Price Density |
| Price |
Predictive Modules for Tarsus Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Tarsus Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Tarsus Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Tarsus Pharmaceuticals is not an exception. The market had few large corrections towards the Tarsus Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Tarsus Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Tarsus Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.09 | |
β | Beta against Dow Jones | 0.48 | |
σ | Overall volatility | 5.54 | |
Ir | Information ratio | -0.05 |
Tarsus Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Tarsus Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Tarsus Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Tarsus Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 182.95 M. Net Loss for the year was (115.55 M) with profit before overhead, payroll, taxes, and interest of 278.26 M. | |
| Tarsus Pharmaceuticals currently holds about 245.36 M in cash with (83.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.2. | |
| Tarsus Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Strs Ohio Has 624,000 Stake in Tarsus Pharmaceuticals, Inc. TARS |
Tarsus Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Tarsus Stock often depends not only on the future outlook of the current and potential Tarsus Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tarsus Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 37.6 M | |
| Cash And Short Term Investments | 291.4 M |
Tarsus Pharmaceuticals Fundamentals Growth
Tarsus Stock prices reflect investors' perceptions of the future prospects and financial health of Tarsus Pharmaceuticals, and Tarsus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tarsus Stock performance.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 2.46 B | ||||
| Shares Outstanding | 42.45 M | ||||
| Price To Book | 8.18 X | ||||
| Price To Sales | 7.48 X | ||||
| Revenue | 182.95 M | ||||
| Gross Profit | 278.26 M | ||||
| EBITDA | (106.48 M) | ||||
| Net Income | (115.55 M) | ||||
| Cash And Equivalents | 245.36 M | ||||
| Cash Per Share | 9.20 X | ||||
| Total Debt | 72.45 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 21.36 X | ||||
| Book Value Per Share | 7.89 X | ||||
| Cash Flow From Operations | (83.03 M) | ||||
| Earnings Per Share | (1.99) X | ||||
| Market Capitalization | 2.74 B | ||||
| Total Asset | 376.99 M | ||||
| Retained Earnings | (360.21 M) | ||||
| Working Capital | 276.09 M | ||||
About Tarsus Pharmaceuticals Performance
Assessing Tarsus Pharmaceuticals' fundamental ratios provides investors with valuable insights into Tarsus Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Tarsus Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 85.74 | 81.46 | |
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.47) | (0.49) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (0.59) | (0.56) |
Things to note about Tarsus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Tarsus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tarsus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tarsus Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 182.95 M. Net Loss for the year was (115.55 M) with profit before overhead, payroll, taxes, and interest of 278.26 M. | |
| Tarsus Pharmaceuticals currently holds about 245.36 M in cash with (83.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.2. | |
| Tarsus Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Strs Ohio Has 624,000 Stake in Tarsus Pharmaceuticals, Inc. TARS |
- Analyzing Tarsus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tarsus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Tarsus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tarsus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tarsus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tarsus Pharmaceuticals' stock. These opinions can provide insight into Tarsus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.